Akoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial Day
16 December 2022 - 08:00AM
Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology
Company®, today highlighted the latest wave of spatial biology
innovations, new products, and partnerships that further accelerate
and simplify spatial signature discovery and validation, at its
second annual Spatial Day event. Company leadership and leading
scientists came together to discuss advancements in spatial biology
and the progress towards delivering spatial signatures to advance
the field of precision medicine.
Akoya’s flagship platforms, PhenoCycler®-Fusion and PhenoImager®
HT, enable a deeper understanding of biology, disease progression,
and response to therapy through rapid and scalable multiomic
mapping of tissue architecture.
At this year’s Spatial Day, the company introduced a suite of
ready-to-use PhenoCode™ panels to accelerate the adoption and
utilization of the company’s spatial phenotyping solutions for
discovery and translational research. The company also announced
PhenoCycler-Fusion platform improvements to double throughput and
an expanded list of software and data analysis partners to provide
customers with a range of flexible and fit-for-purpose data
analysis solutions.
“With the launch of our PhenoCycler-Fusion system, we set a new
standard for accelerating spatial biology at scale, allowing
meaningful conclusions to be drawn from increasingly larger and
more complex cohorts of samples,” said Brian McKelligon, Chief
Executive Officer of Akoya Biosciences. “With our new PhenoCode
Discovery and Signature Panels, rapidly expanding and powerful
options for data analysis, and instrument enhancements, we deliver
a higher standard enabling the most productive and scalable spatial
biology workflow, putting even more power into the hands of our
customers.”
The following new product introductions to Akoya’s end-to-end
spatial biology solutions address specific requirements of
discovery, translational, and clinical researchers.
PhenoCode Ready-to-Use Panels to Accelerate Spatial
Discovery and Signature Development – To further
accelerate system utilization, Akoya is introducing a series of
ready-to-use panels for use across the entire portfolio. Launched
at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
this year, the PhenoCode Signature Panels for the PhenoImager
instruments are based on a novel barcoded chemistry and include
markers for phenotyping the tumor microenvironment and immune
status. The customizable panels provide translational and clinical
researchers with a ready-made solution to rapidly advance biomarker
programs. Additional PhenoCode Signature Panels will be announced
and introduced in 2H 2023. In 1H 2023, PhenoCode Discovery Panels
will be introduced for the PhenoCycler-Fusion system. These
discovery panels will focus on providing comprehensive coverage of
key biomarkers in oncology and inflammatory disease. Similar to the
PhenoCode Signature Panels, additional PhenoCode Discovery Panels
will be introduced in 2H 2023, expanding into additional
therapeutic areas such as neuroscience. The company also detailed
the rollout of a co-marketed offering with Bio-Techne in 1H 2023
and the introduction of Akoya’s spatial transcriptomics offering in
2H 2023.
An Ecosystem of Software Partners to Simplify Data
Analysis – The growing adoption of spatial biology across
all market segments is catalyzing development of a rapidly
expanding list of organizations focused on developing data analysis
and software solutions. To capitalize on this, and for the benefit
of the company’s customers, Akoya continues to expand on its
current ecosystem of software partnerships to now include
OracleBio, Indica Labs, and Enable Medicine. These are in addition
to Akoya’s long-standing partnerships with both Visiopharm and
PathAI. The result is a suite of tools and services that can enable
turnkey analysis of whole-slide, high-plex data to meet the needs
of all customer segments.
The key to enabling these partnerships is Akoya’s
standardization and compression of data generated on the company’s
platforms. Spatial data generated by the PhenoCycler-Fusion and
PhenoImager HT platforms are compressed into a manageable size and
a standardized file format, termed QPTIFF, for downstream storage
and analysis. This is done in real time on the instrument and
utilizes a proprietary algorithm that reduces file sizes from
terabytes to gigabytes. By reducing file sizes, researchers can
easily manage their data and eliminate lengthy post-processing
steps, allowing them to confidently scale-up spatial discovery
efforts with larger panels and study sizes. With this suite of
software partners, Akoya meets the diverse data analysis needs of
discovery, translational, and clinical researchers.
Instrument Enhancements for Higher Throughput and
Automation – New enhancements to the PhenoCycler-Fusion
system enable a doubling of the platform’s throughput. The
PhenoCycler-Fusion 2.0 workflow includes a multi-slide carrier
which enables labs to process twice as many samples per week and
will be available in 1H 2023. The upgrade also enables automation
of Bio-Techne’s RNAscope® assay for visualization and spatial
detection of single RNA molecules.
A recording of Akoya’s Spatial Day Event can be accessed
at akoyabio.com/spatialday.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research: PhenoCode™ Panels and
PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.
To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:Priyam ShahSr. Director,
Investor RelationsAkoya Biosciencesinvestors@akoyabio.com
Media Contact:Christine
Quern617-650-8497media@akoyabio.com
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Mar 2023 to Mar 2024